WebJun 26, 2024 · The trial design and the protocol were approved by the relevant national regulatory authorities and national and/or local ethics committees. All patients provided written informed consent. ... The AEGEAN study showed that implementation adherence and persistence rates with apixaban therapy for NVAF are high over the first 48 weeks of ... WebApr 9, 2024 · AEGEAN is a randomized, double-blind, placebo-controlled, multicenter, global trial in resectable stage IIA-IIIB (tumor ≥4 cm or node-positive) NSCLC without EGFR or …
Curative-Intent Treatment with Durvalumab in Early …
WebAegean. 3.2. Study design In a total sample of approximately 10 healthy volunteers, the number of which was determined through a special statistical program for calculating the required sample of the research to draw safe and reliable conclusions, a nutritional intervention – clinical study of cross-over design will be carried out. WebMar 10, 2024 · Positive high-level results from a planned interim analysis of the AEGEAN phase III, placebo-controlled trial showed that treatment with AstraZeneca’s Imfinzi (durvalumab) in combination with neoadjuvant chemotherapy before surgery and as adjuvant monotherapy after surgery demonstrated a statistically significant and clinically … from nairobi for example crossword
Durvalumab Plus Chemotherapy Improves pCR in Resectable …
WebJun 30, 2024 · AEGEAN is a randomized, double-blind, placebo-controlled, multicenter, global trial evaluating durvalumab as perioperative treatment in patients with resectable … WebMar 9, 2024 · AEGEAN is a randomized, double-blind, multi-center, placebo-controlled global Phase III trial evaluating IMFINZI as perioperative treatment for patients with resectable Stage IIA-IIIB (Eighth ... from net income to free cash flow